The interferon-related developmental regulator 1 is used by human papillomavirus to suppress NFκB activation

Nature Communications

Volumn 6, Issue , 2015, Pages

  Tummers, Bart ^a   Goedemans, Renske ^a   Pelascini, Laetitia P L ^a   Jordanova, Ekaterina S ^b   Van Esch, Edith M G ^a   Meyers, Craig ^c   Melief, Cornelis J M ^a   Boer, Judith M ^a,d,e   Van Der Burg, Sjoerd H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Center of Gynaecologic Oncology Amsterdam   (Netherlands)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

^d SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^e Netherlands Bioinformatics Center   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; CETUXIMAB; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; ENTINOSTAT; FIBROBLAST GROWTH FACTOR; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERFERON RELATED DEVELOPMENTAL REGULATOR 1; INTERLEUKIN 8; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NERVE GROWTH FACTOR; RANTES; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELA K310; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; HISTONE DEACETYLASE; IFRD1 PROTEIN, HUMAN; IMMEDIATE EARLY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR NECROSIS FACTOR;

CANCER; IMMUNE SYSTEM; INFECTIOUS DISEASE; PERSISTENCE; VIRUS;

ADAPTIVE IMMUNITY; ANIMAL CELL; ARTICLE; CANCER CELL; CERVICAL CANCER CELL LINE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; FEMALE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 20; IMMUNOCOMPETENT CELL; IN VITRO STUDY; INNATE IMMUNITY; KERATINOCYTE; MOUSE; MYOBLAST; NONHUMAN; PROTEIN ACETYLATION; PROTEIN EXPRESSION; TRANSCRIPTION INITIATION; UPREGULATION; VIRION; VIRUS GENOME; WART VIRUS; ACETYLATION; BIOSYNTHESIS; CELL CULTURE; IMMUNE EVASION; METABOLISM; PAPILLOMAVIRIDAE; PHYSIOLOGY; SIGNAL TRANSDUCTION;

HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRIDAE;

ACETYLATION; CELLS, CULTURED; CYTOKINES; HISTONE DEACETYLASES; HUMANS; IMMEDIATE-EARLY PROTEINS; IMMUNE EVASION; INTERFERON-GAMMA; NF-KAPPA B; PAPILLOMAVIRIDAE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84924873108     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7537     Document Type: Article

References (49)

1. Doorbar, J. Molecular biology of human papillomavirus infection and cervical cancer. Clin. Sci. 110, 525-541 (2006).
2. Frazer, I. H. Interaction of human papillomaviruses with the host immune system: a well evolved relationship. Virology 384, 410-414 (2009).
3. Karim, R. et al. Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes.PLoS ONE6, e17848 (2011).
4. Richardson, H. et al. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol. Biomarkers Prev. 12, 485-490 (2003).
5. van der Burg, S. H. & Melief, C. J. Therapeutic vaccination against human papilloma virus induced malignancies. Curr. Opin. Immunol. 23, 252-257 (2011).
6. zur Hausen, H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2, 342-350 (2002).
7. Hasan, U. A. et al. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J. Immunol. 178, 3186-3197 (2007).
8. Karim, R. et al. Human papillomavirus (HPV) upregulates the cellular deubiquitinase UCHL1 to suppress the keratinocyte's innate immune response. PLoS Pathog. 9, e1003384 (2013).
9. Reiser, J. et al. High-risk human papillomaviruses repress constitutive kappa interferon transcription via E6 to prevent pathogen recognition receptor and antiviral-gene expression. J. Virol. 85, 11372-11380 (2011).
10. Sunthamala, N. et al. E2 proteins of high risk human papillomaviruses down-modulate STING and IFN-kappa transcription in keratinocytes. PLoS ONE 9, e91473 (2014).
11. Termini, L. et al. Characterization of global transcription profile of normal and HPV-immortalized keratinocytes and their response to TNF treatment. BMC Med. Genomics 1, 29 (2008).
12. Tummers, B. et al. CD40-mediated amplification of local immunity by epithelial cells is impaired by HPV. J. Invest. Dermatol. 134, 2918-2927 (2014).
13. Chang, Y. E. & Laimins, L. A. Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31. J. Virol. 74, 4174-4182 (2000).
14. Hong, S., Mehta, K. P. & Laimins, L. A. Suppression of STAT-1 expression by human papillomaviruses is necessary for differentiation-dependent genome amplification and plasmid maintenance. J. Virol. 85, 9486-9494 (2011).
15. Nees, M. et al. Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. J. Virol. 75, 4283-4296 (2001).
16. Zhou, F., Chen, J. & Zhao, K. N. Human papillomavirus 16-encoded E7 protein inhibits IFN-gamma-mediated MHC class I antigen presentation and CTL-induced lysis by blocking IRF-1 expression in mouse keratinocytes. J. Gen. Virol. 94, 2504-2514 (2013).
17. Chen, L. F. & Greene, W. C. Shaping the nuclear action of NF-kappaB. Nat. Rev. Mol. Cell Biol. 5, 392-401 (2004).
18. Conway, M. J. & Meyers, C. Replication and assembly of human papillomaviruses. J. Dent. Res. 88, 307-317 (2009).
19. McLaughlin-Drubin, M. E., Christensen, N. D. & Meyers, C. Propagation, infection, and neutralization of authentic HPV16 virus. Virology 322, 213-219 (2004).
20. Meyers, C., Mayer, T. J. & Ozbun, M. A. Synthesis of infectious human papillomavirus type 18 in differentiating epithelium transfected with viral DNA. J. Virol. 71, 7381-7386 (1997).
21. Lee, D., Lee, B., Kim, J., Kim, D. W. & Choe, J. cAMP response element-binding protein-binding protein binds to human papillomavirus E2 protein and activates E2-dependent transcription. J. Biol. Chem. 275, 7045-7051 (2000).
22. Quinlan, E. J., Culleton, S. P., Wu, S. Y., Chiang, C. M. & Androphy, E. J. Acetylation of conserved lysines in bovine papillomavirus E2 by p300. J. Virol. 87, 1497-1507 (2013).
23. Gu, Y. et al. Identification of IFRD1 as a modifier gene for cystic fibrosis lung disease. Nature 458, 1039-1042 (2009).
24. Micheli, L. et al. PC4/Tis7/IFRD1 stimulates skeletal muscle regeneration and is involved in myoblast differentiation as a regulator of MyoD and NF-kappaB. J. Biol. Chem. 286, 5691-5707 (2011).
25. Xue, Y. et al. HPV16 E2 is an immediate early marker of viral infection, preceding E7 expression in precursor structures of cervical carcinoma. Cancer Res. 70, 5316-5325 (2010).
26. von Knebel Doeberitz, M., Gissmann, L. & zur Hausen, H. Growth-regulating functions of human papillomavirus early gene products in cervical cancer cells acting dominant over enhanced epidermal growth factor receptor expression. Cancer Res. 50, 3730-3736 (1990).
27. Vietor, I. & Huber, L. A. Role of TIS7 family of transcriptional regulators in differentiation and regeneration. Differentiation 75, 891-897 (2007).
28. Kim, M. K. et al. Human papillomavirus type 16 E5 oncoprotein as a new target for cervical cancer treatment. Biochem. Pharmacol. 80, 1930-1935 (2010).
29. Bruzzese, F. et al. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J. Cell. Physiol. 226, 2378-2390 (2011).
30. Liu, N. et al. Blocking the class I histone deacetylase ameliorates renal fibrosis and inhibits renal fibroblast activation via modulating TGF-beta and EGFR signaling. PLoS ONE 8, e54001 (2013).
31. Heusinkveld, M. et al. M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4 + Th1 cells. J. Immunol. 187, 1157-1165 (2011).\
32. Feng, W., Duan, X., Liu, J., Xiao, J. & Brown, R. E. Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions. Int. J. Clin. Exp. Pathol. 2, 249-260 (2009).
33. Kalinowski, A. et al. EGFR activation suppresses respiratory virus-induced IRF1-dependent CXCL10 production. Am. J. Physiol. Lung Cell. Mol. Physiol. 307, L186-L196 (2014).
34. Mascia, F., Mariani, V., Girolomoni, G. & Pastore, S. Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am. J. Pathol. 163, 303-312 (2003).
35. Paul, T. et al. Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients. Eur. J. Cancer 50, 1855-1863 (2014).
36. Pastore, S. et al. ERK1/2 regulates epidermal chemokine expression and skin inflammation. J. Immunol. 174, 5047-5056 (2005).
37. Vandermark, E. R. et al. Human papillomavirus type 16 E6 and E 7 proteins alter NF-kB in cultured cervical epithelial cells and inhibition of NF-kB promotes cell growth and immortalization. Virology 425, 53-60 (2012).
38. Caberg, J. H. et al. Increased migration of Langerhans cells in response to HPV16 E6 and E7 oncogene silencing: role of CCL20. Cancer Immunol. Immunother. 58, 39-47 (2009).
39. Havard, L., Rahmouni, S., Boniver, J. & Delvenne, P. High levels of p105 (NFKB1) and p100 (NFKB2) proteins in HPV16-transformed keratinocytes: role of E6 and E7 oncoproteins. Virology 331, 357-366 (2005).
40. Avvakumov, N., Torchia, J. & Mymryk, J. S. Interaction of the HPV E7 proteins with the pCAF acetyltransferase. Oncogene 22, 3833-3841 (2003).
41. Bernat, A., Avvakumov, N., Mymryk, J. S. & Banks, L. Interaction between the HPV E7 oncoprotein and the transcriptional coactivator p300. Oncogene 22, 7871-7881 (2003).
42. Huang, S. M. & McCance, D. J. Down regulation of the interleukin-8 promoter by human papillomavirus type 16 E6 and E7 through effects on CREB binding protein/p300 and P/CAF. J. Virol. 76, 8710-8721 (2002).
43. Spitkovsky, D., Hehner, S. P., Hofmann, T. G., Moller, A. & Schmitz, M. L. The human papillomavirus oncoprotein E7 attenuates NF-kappa B activation by targeting the Ikappa B kinase complex. J. Biol. Chem. 277, 25576-25582 (2002).
44. Hasan, U. A. et al. The human papillomavirus type 16 E7 oncoprotein induces a transcriptional repressor complex on the Toll-like receptor 9 promoter. J. Exp. Med. 210, 1369-1387 (2013).
45. Bodily, J. M., Mehta, K. P. & Laimins, L. A. Human papillomavirus E7 enhances hypoxia-inducible factor 1-mediated transcription by inhibiting binding of histone deacetylases. Cancer Res. 71, 1187-1195 (2011).
46. Hiscott, J., Nguyen, T. L., Arguello, M., Nakhaei, P. & Paz, S. Manipulation of the nuclear factor-kappaB pathway and the innate immune response by viruses. Oncogene 25, 6844-6867 (2006).
47. Le Negrate, G. Viral interference with innate immunity by preventing NF-kappaB activity. Cell. Microbiol. 14, 168-181 (2012).
48. Ning, Z. et al. The N terminus of orf virus-encoded protein 002 inhibits acetylation of NF-kappaB p65 by preventing Ser(276) phosphorylation. PloS ONE 8, e58854 (2013).
49. Granja, A. G., Sabina, P., Salas, M. L., Fresno, M. & Revilla, Y. Regulation of inducible nitric oxide synthase expression by viral A238L-mediated inhibition of p65/RelA acetylation and p300 transactivation. J. Virol. 80, 10487-10496 (2006).